In this study, we reveal for the first time that EGF4KDEL, a BLT targeting both EGFR and IL-4R, shows potent activity against MM both in vitro and in vivo and has significantly reduced toxicity when given therapeutically. Here, IL4R is linked to Miyoshi myopathy.